

PATENT COOPERATION TREATY

From the INTERNATIONAL SEARCHING AUTHORITY

To:

Davies Collison Cave
1 Little Collins Street
MELBOURNE VIC 3000

PCT

NOTIFICATION OF TRANSMITTAL OF THE INTERNATIONAL SEARCH REPORT OR THE DECLARATION

(PCT Rule 44.1)

Date of mailing
(day/month/year) 13 NOV 2003

Applicant's or agent's file reference
12328250/TDO/LM

FOR FURTHER ACTION See paragraphs 1 and 4 below

International application No.
PCT/AU03/01154

International filing date
5 September 2003

Applicant

MEDVET SCIENCE PTY LTD et al

1. ☒ The applicant is hereby notified that the international search report has been established and is transmitted herewith.

Filing of amendments and statement under Article 19:

The applicant is entitled, if he so wishes, to amend the claims of the international application (see Rule 46):

When? The time limit for filing such amendments is normally two months from the date of transmittal of the international search report.

Where? Directly to the International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland
Facsimile No.: (41-22) 740.14.35

For more detailed instructions, see the notes on the accompanying sheet.

2. ☐ The applicant is hereby notified that no international search report will be established and that the declaration under Article 17(2)(a) to that effect is transmitted herewith.

3. ☐ With regard to the protest against payment of (an) additional fee(s) under Rule 40.2, the applicant is notified that:

☐ the protest together with the decision thereon has been transmitted to the International Bureau together with the applicant's request to forward the texts of both the protest and the decision thereon to the designated Offices.

☐ no decision has been made yet on the protest; the applicant will be notified as soon as a decision is made.

4. **Reminders**

Shortly after 18 months from the priority date, the international application will be published by the International Bureau.

If the applicant wishes to avoid or postpone publication, a notice of withdrawal of the international application, or of the priority claim, must reach the International Bureau as provided in Rules 90bis.1 and 90bis.3, respectively, before the completion of the technical preparations for international publication.

Within 19 months from the priority date, but only in respect of some designated Offices, a demand for international preliminary examination must be filed if the applicant wishes to postpone the entry into the national phase until 30 months from the priority date (in some Offices even later);

otherwise, the applicant must, within 20 months from the priority date, perform the prescribed acts for entry into the national phase before those designated Offices.

In respect of other designated Offices, the time limit of 30 months (or later) will apply even if no demand is filed within 19 months.

See the Annex to Form PCT/IB/301 and, for details about the applicable time limits, Office by Office, see the *PCT Applicant's Guide*, Volume II, National Chapters and the WIPO Internet site.

Name and mailing address of the ISA/AU

AUSTRALIAN PATENT OFFICE
PO BOX 200, WODEN ACT 2606, AUSTRALIA
E-mail address: pct@ipaustalia.gov.au
Facsimile No. (02) 6285 3929

Authorized officer

JASON MACKENZIE
Telephone No. (02) 6283 7934

BEST AVAILABLE COPY

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference 12328250/TDO/LM	FOR FURTHER ACTION see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. PCT/AU03/01154	International filing date (day/month/year) 5 September 2003	(Earliest) Priority Date (day/month/year) 6 September 2002
Applicant MEDVET SCIENCE PTY LTD et al		

This international search report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This international search report consists of a total of 3 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

1. **Basis of the report**
 - a. With regard to the language, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.
 - ☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).
 - b. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of the sequence listing:
 - ☐ contained in the international application in written form.
 - ☐ filed together with the international application in computer readable form.
 - ☐ furnished subsequently to this Authority in written form.
 - ☐ furnished subsequently to this Authority in computer readable form.
 - ☐ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
 - ☐ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.
2. ☐ Certain claims were found unsearchable (See Box I).
3. ☐ Unity of invention is lacking (See Box II).
4. With regard to the title,
 - ☐ the text is approved as submitted by the applicant.
 - ☒ the text has been established by this Authority to read as follows: A METHOD OF MODULATING ENDOTHELIAL CELL ACTIVITY
5. With regard to the abstract,
 - ☒ the text is approved as submitted by the applicant
 - ☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.
6. The figure of the drawings to be published with the abstract is Figure No. **Figure 5a**
 - ☐ as suggested by the applicant.
 - ☒ because the applicant failed to suggest a figure
 - ☐ because this figure better characterizes the invention
 - ☐ None of the figures

BEST AVAILABLE COPY

INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU03/01154

A. CLASSIFICATION OF SUBJECT MATTERInt. Cl. ⁷: A61K 38/45, 31/4355, 31/407; A61P 3/04, 9/14, 27/00, 29/00, 35/04

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
 MEDLINE, DWPI: Protein, Kinase, Zeta, PKC, DNA, Gene, Mutant, Endothelial, Permeability, Angiopoietin, Chelerythrine, Bisindoylmaleimide, Angiogenesis, Tumor, Arthritis, Crohns, Obesity, Endometriosis, Psoriasis, Osler, Webber.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	The Merck Index (12 th ed). Published by Merck & CO., INC. Entry 886: Aspirin. See the whole entry.	48
X	Frey et al., (2002). PKC ζ regulates TNF- α -induced activation of NADPH oxidase in endothelial cells. Circulation Research 90:1012-1019. See the whole document, particularly the abstract, Materials, Figures 4-7, and the last paragraph of the discussion.	1-45
X	Rahman et al., (2000). Protein kinase C- ζ mediates TNF- α -induced ICAM-1 gene transcription in endothelial cells. American Journal of Physiology. Cell Physiology 279:C906-C914. See the whole document, particularly the abstract, and Figures 4, 8, and 9.	1-26

☒ Further documents are listed in the continuation of Box C☐ See patent family annex

- * Special categories of cited documents:
- | | |
|---|--|
| "A" document defining the general state of the art which is not considered to be of particular relevance | "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention |
| "E" earlier application or patent but published on or after the international filing date | "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone |
| "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) | "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art |
| "O" document referring to an oral disclosure, use, exhibition or other means | "&" document member of the same patent family |
| "P" document published prior to the international filing date but later than the priority date claimed | |

Date of the actual completion of the international search
30 October 2003

Date of mailing of the international search report

13 NOV 2003

Name and mailing address of the ISA/AU

AUSTRALIAN PATENT OFFICE
 PO BOX 200, WODEN ACT 2606, AUSTRALIA
 E-mail address: pct@ipaustralia.gov.au
 Facsimile No. (02) 6285 3929

Authorized officer

JASON MACKENZIE

Telephone No : (02) 6283 7934

BEST AVAILABLE COPY

INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU03/01154

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Wellner et al., (1999). The proliferative effect of vascular endothelial growth factor requires protein kinase C- α and protein kinase C- ζ . Arteriosclerosis, Thrombosis and Vascular Biology 19(1):178-185. See the whole document, particularly the abstract, Figures 4-7, and last paragraph of the discussion.	1-26
X	US 6410597 B1 (Bieberich et al.), June 25 2002. See the whole document, particularly the abstract, column 2 lines 24-45, and all claims.	48
X	US 2002/0091082 A1 (Aiello), July 11 2002. See the whole document, particularly paragraphs 4, 6-10, 16, 26, 32, 33-41, 46, 70, 63-156, and examples 8-11.	1-48
A	Hempel et al., (1999). Calcium antagonists ameliorate ischemia-induced endothelial cell permeability by inhibiting protein kinase C. Circulation 99(19):2523-2529. See the whole document.	1-47
A	Battle et al., (1994). Antipeptide antibodies directed against the C-terminus of protein kinase C ζ (PKC ζ) react with a Ca ²⁺ -and TPA-sensitive PKC in HT-29 human intestinal epithelial cells. FEBS Letters 344:161-165. See the whole document.	1-47
A	Mattila et al., (1994). Expression of six protein kinase C isotypes in endothelial cells. Life Sciences 55(16):1253-1260. See the whole document.	1-47

BEST AVAILABLE COPY